Lucid DiagnosticsLUCD
Market Cap: $40.7M
About: Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Employees: 70
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
13% more funds holding
Funds holding: 30 [Q1] → 34 (+4) [Q2]
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
3% more capital invested
Capital invested by funds: $1.69M [Q1] → $1.74M (+$50.7K) [Q2]
0.25% less ownership
Funds ownership: 4.29% [Q1] → 4.04% (-0.25%) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Ascendiant Capital Edward Woo 38% 1-year accuracy 18 / 48 met price target | 779%upside $7.25 | Buy Maintained | 10 Sept 2024 |
Canaccord Genuity Kyle Mikson 57% 1-year accuracy 12 / 21 met price target | 264%upside $3 | Buy Maintained | 13 Aug 2024 |
Needham Mike Matson 61% 1-year accuracy 69 / 114 met price target | 203%upside $2.50 | Buy Reiterated | 13 Aug 2024 |
Financial journalist opinion
Based on 3 articles about LUCD published over the past 30 days